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summary
The objective of this review is to update the recommendations of the 2010 Italian Consensus on the use of 
methotrexate (MTX) in rheumatoid arthritis (RA) and other rheumatic diseases. The literature published be-
tween 2008 and 2012 was systematically reviewed and updated recommendations on MTX use in rheumatic 
diseases, particularly RA, were formulated. These recommendations were approved by a panel of expert Italian 
Rheumatologists. A total of 10,238 references were identified, among which 70 studies were selected for criti-
cal evaluation. Sufficient evidence had accumulated to warrant changes to several of the recommendations in 
the new version. A new recommendation for patients with RA who are in MTX-induced clinical remission was 
also proposed and approved by the panel. Updated recommendations for the use of MTX in patients with RA 
or other rheumatologic disease are proposed. 
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n	 INTRODUCTION 
In 2008, the international 3E Initiative resulted in development of 10 evidence-
based recommendations for the use of 
methotrexate (MTX) in rheumatic dis-
orders based on analysis of scientific lit-
erature published before November 2007 
and expert opinion. In 2009, national 
recommendations on the use of MTX 
in Rheumatology were formulated at an 
Italian Consensus Meeting. On this occa-
sion, the 10 international recommenda-
tions along with five recommendations 
added by the Italian team, were discussed 
and reformulated, including an appraisal of 
the strength of the recommendation in the 
final version. The aim of the initiative was 
to standardize the Italian therapeutic ap-
proach to the use of MTX in rheumatoid 
arthritis (RA) and other rheumatic diseas-
es to avoid heterogeneous conduct based 
on personal experience (1). The ICARUS 
Project was established with the aim of up-
dating the previous recommendations, fo-
cusing on important aspects such as safety, 
starting dose, step-up strategy and route of 
administration. 
n	 METHODS OF RESEARCH
Under the guidance of a Scientific Committee 
comprised of six experts, eight bibliographic 
fellows specialized in Rheumatology sys-
tematically reviewed the scientific literature 
available regarding the 2010 Italian recom-
mendations on the use of MTX in RA. In 
particular, previous recommendations were 
reassessed in light of studies on MTX pub-
lished after November 2007 in order to ad-
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A total of 15 issues were identified and 
submitted to specific rephrasing and coding 
following the PICO method (Population, 
Intervention, Comparison, Outcome), in 
order to facilitate the literature review. 
PubMed and Embase were consulted, se-
lecting the literature related to the thera-
peutic use of MTX in rheumatic diseases 
(particularly RA) published between 2008 
and September 2012. 
The literature search was conducted ac-
cording to Cochrane collaboration guide-
lines (2) and the results were critically 
analysed by the bibliographic fellows, fol-
lowing the principles of evidence-based 
medicine (3). 
Each issue was analysed independently by 
two fellows, who produced preliminary ob-
servations and assigned a level of scientific 
evidence (4); finally, the updated issues 
were presented to the panel of experts in 
order to define topics for discussion. 
Subsequently, a group of 36 Italian 
Rheumatologists attended a meeting struc-
tured in two specific sessions. In the first 
session, the participants were divided into 
coordinator-led subgroups in which the 
topics that emerged from the review were 
discussed, proposals were made, and pre-
liminary recommendations were formu-
lated. In the second plenary session, the 
text of the preliminary recommendations 
was discussed and their acceptability de-
termined by a Delphi-like procedure. 
The text of the updated recommendations 
was thus finalized, adding the level of 
agreement that had emerged from the ple-
nary vote. 
n	 RESULTS
Papers evaluated and reasons for exclusion 
are shown in Figure 1. Fifteen updated rec-
ommendations were released; to note that 
the original recommendation 7 (regarding 
MTX-naïve patients or MTX non-respond-
er patients) was grouped with recommen-
dations 11 and 12, due to the presence of 
many overlapping elements. 
Moreover, a new recommendation was 
introduced (recommendation 15) on the 
therapeutic approach for RA patients who 
have achieved clinical remission with 
MTX, alone or in combination with other 
agents (Table I). 
Recommendation 1: work-up for metho-
trexate candidates 
The work-up for RA patients who are MTX 
candidates should include the following 
tests: liver function tests; serum albumin; 
blood cell counts; serum creatinine; hepa-
titis B and C serology; chest X-ray. MTX 
treatment should not be introduced during 
pregnancy or in the presence of hepatic cir-
rhosis, severe renal function impairment; 
alcohol abuse; bone marrow depression; 
or active hepatitis B or C (4; C). 
The prerequisite pregnancy test has been 
removed in the latest version, but the warn-
ing remains that this teratogenic drug must 
not be used when pregnancy is confirmed 
or suspected. Specific concomitant diseas-
es and alcohol abuse remain contraindica-
tions to the administration of MTX (5-11). 
In particular, the literature supports the po-
tential hepatotoxicity of MTX and its po-
tential role in the reactivation of hepatitis 
B, including acute fulminant hepatitis.
The recommendation was approved by 
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Table I - 2012 recommendations for the use of methotrexate in rheumatoid arthritis and in other rheumatic 
diseases.
recommendation (level of evidence; strength of the recommendation) Changes in 
comparison with 
the 2010 version
1. The work-up for RA patients who are MTX candidates should include the following tests: liver 
function tests; serum albumin; blood cell counts; serum creatinine; hepatitis B and C serology; 
chest X-ray. MTX treatment should not be introduced during pregnancy or in the presence of 
hepatic cirrhosis, severe renal function impairment; alcohol abuse; bone marrow depression; or 
active hepatitis B or C (4; C). 
Partially modified 
2. The therapeutic range of MTX is 7.5-25 mg/week. The optimal initial strategy is a starting 
dose of 12.5-15 mg/week (1b; B). In the absence of adverse events and/or subjective intoleran-
ce, in patients with early RA, close monitoring of therapeutic efficacy and therapeutic targets 
with rapid up-titration (5 mg/week a month) is more effective (1b; B). As MTX-related toxicity is 
dose-dependent, the maximum weekly dose of 25 mg (2b; B) should not be exceeded. It can 
be given initially by oral or parenteral route. Oral bioavailability of the drug varies, in particular at 
high doses (3b; B). Parenteral MTX can increase efficacy with a similar safety profile (1b; B). In 
patients refractory to oral MTX, switching to parenteral administration may be a useful strategy 
before introducing other therapies (2b; B). 
Extensively 
modified 
3. Weekly supplementation with folic acid (5-10 mg/week) should be administered to reduce 
the risk of adverse events/intolerance (1a; A). In most cases, it should be taken 24 hours after 
MTX. To date there is sufficient evidence that folic acid supplements do not nullify the clinical 
efficacy of MTX (1a; A). 
Partially modified 
4. Transaminases (AST, ALT) are the most useful laboratory parameters for monitoring liver to-
xicity due to MTX. CBC and renal function tests should also be performed in patients receiving 
MTX. These tests should be performed every 2 weeks for the first month, then every 4-12 weeks 
to check for hepatic, haematological or renal toxicity (1; A). Neither chest X-rays nor respiratory 
function tests allow prediction of the risk of MTX pneumonia (4; C).
Unchanged 
5. When liver enzymes increase (≥2x normal upper limit), the dosage of MTX must be reduced or 
administration discontinued temporarily. Persistently high values indicate that treatment should 
be discontinued. A liver biopsy is indicated when liver enzyme values are persistently high de-
spite treatment discontinuation and when other risk factors for liver disease are present (2b; C).
Unchanged 
6. According to its safety profile, MTX may be used for long-term therapy. Discontinuation rates 
due to toxicity are similar to those in patients treated with hydroxychloroquine or leflunomide, 
and lower than those in patients receiving gold salts or sulfasalazine (3b; B). The most frequent 
side effects during treatment with MTX are gastrointestinal disturbances, with constant inciden-
ce over time, and hypertransaminasemia, especially during the first 5 years. The discontinuation 
rate due to hepatotoxicity is about 5%. Alcohol consumption should be avoided, because it 
appears to be an adjunctive risk factor for the development of hepatic fibrosis. MTX is not a 
significant risk factor for the development of infections, including severe infections. In patients 
with RA, MTX, and DMARDs in general, are associated with a greater incidence of tuberculosis 
reactivation (3b; B). MTX does not appear to be a risk factor for the development of neoplasms 
(3b; B). MTX can prolong the survival of RA patients by reducing cardiovascular mortality (2a; A).
Partially modified 
7. The administration of MTX (at ≤10 mg/week) can be continued in RA patients who undergo 
orthopaedic surgery as MTX does not affect the incidence of perioperative surgical complica-
tions whereas treatment discontinuation may increase the incidence of disease reactivation. 
MTX dosage reduction or treatment discontinuation may be considered for doses ≥10 mg per 
week in patients undergoing major surgery (1b; B).
Unchanged 
8. MTX must be discontinued at least 3 months before conception (both in men and in women), 
it must be strictly forbidden during pregnancy and avoided during breastfeeding (4; C).
Unchanged 
9. MTX must be considered the DMARD of first choice in RA patients both alone and in combi-
nation (with low dosage glucocorticoid and/or other DMARDs) (2b; B).
Partially modified 
10. In patients that are non-responders to MTX at the maximum tolerated dosage, combina-
tion therapy can be started with DMARD or a biological agent (1b; B). Currently, addition of a 
biological agent should be preferred in patients with poor prognostic factors or documented 
radiological progression (1b; B).
Partially modified 
11. Administration of MTX must be temporarily discontinued in patients who develop severe 
infections (any infection requiring hospitalization and/or intravenous antibiotics/antifungals and/
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Recommendation 2: methotrexate thera-
peutic strategy
The therapeutic range of MTX is 7.5-25 
mg/week. The optimal initial strategy is 
a starting dose of 12.5-15 mg/week (1b). 
In the absence of adverse events and/or 
subjective intolerance, in patients with 
early RA, close monitoring of therapeu-
tic efficacy and therapeutic targets with 
rapid up-titration (5 mg/week a month) 
is more effective (1b). As MTX-related 
toxicity is dose-dependent, the maximum 
weekly dose of 25 mg (2b) should not be 
exceeded. It can be given initially by oral 
or parenteral route. Oral bioavailability 
of the drug varies, in particular at high 
doses (3b). Parenteral MTX can increase 
efficacy with a similar safety profile (1b). 
In patients refractory to oral MTX, switch-
ing to parenteral administration may be a 
useful strategy before introducing other 
therapies (2b). 
The text has been extensively modified in 
the latest version, focusing on the best ther-
apeutic strategy: the optimal starting and 
step-up doses of MTX have been specified, 
indicating the best timing and methods, 
and considering the safety profile. In addi-
tion, it has been established that parenteral 
MTX is more effective than oral MTX, 
both in MTX naïve patients and in those 
refractory to administration per os (12-16), 
whereas the safety of the two formulations 
is similar.
The recommendation was approved by 
97.3% of participants. 
Recommendation 3: folate supplementa-
tion
Weekly supplementation with folic acid (5-
10 mg/week) should be administered to re-
duce the risk of adverse events/intolerance 
(1a). In most cases, it should be taken 24 
hours after MTX. To date there is sufficient 
evidence that folic acid supplements do not 
nullify the clinical efficacy of MTX (1a). 
The need for both low and high dose folic 
acid supplementation (less than or more 
than 5 mg/week) was confirmed, to reduce 
MTX-related adverse events, such as hepa-
recommendation (level of evidence; strength of the recommendation) Changes in 
comparison with 
the 2010 version
12. Administration of MTX must be discontinued temporarily in patients who develop neutro-
penia (neutrophil count <1000). MTX can be reintroduced with caution in patients who have not 
developed other adverse reactions in association with neutropenia (e.g., infections) and where 
neutropenia has resolved spontaneously, after having considered the concomitant association 
with other risk factors for haematological toxicity (5; D).
Unchanged 
13. MTX can be administered to patients with pre-existing rheumatoid nodules. The dosage 
of MTX should be reduced or administration should be discontinued in patients who develop 
accelerated nodulosis during treatment (5; D).
Unchanged 
14. MTX can be used:
- as a glucocorticoid-sparing drug in the long-term treatment of patients with GCA (1a; A), re-
cent-onset PMR (1b; B), mild-to-moderate SLE with mainly skin and joint involvement (1b; B);
- to induce clinical remission in patients with recent-onset AAV with early systemic involvement 
(1b; B). It can also replace Azathioprine for the maintenance of CTX-induced clinical remission 
(1b; B);
- in PsA, effective on both the cutaneous and the joint component (1b; B).
Recent data also supports the possible use of MTX as an agent that can improve cutaneous 
involvement in recent-onset and widespread systemic sclerosis without significant organ invol-
vement (1b; B).
Partially modified 
15. Therapeutic approach to RA patients who have achieved clinical remission with MTX alone 
or in combination with other agents.
In RA patients treated early (within 1 year of symptoms onset) who achieve and maintain clini-
cal remission for ≥12 months, independently of the tight control therapeutic strategy and the 
DMARD discontinuation methods adopted, treatment (including MTX) can be discontinued in 
the attempt to achieve a drug free remission, which is feasible in 17-29% of patients.
Defined ex novo
MTX, methotrexate; RA, rheumatoid arthritis; DMARD, disease-modifying antirheumatic drug; GCA, giant 
cell arteritis; PMR, rheumatic polymyalgia; SLE, systemic lupus erythematosus; AAV, ANCA-associated 
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totoxicity, and gastrointestinal and mu-
cocutaneous intolerance. However, there 
is no conclusive evidence supporting the 
protection afforded by folic acid against 
bone marrow toxicity, either due to the low 
incidence of these haematological adverse 
events reported with the use of MTX, or to 
the inaccurate definition of this adverse ef-
fect in some studies. In addition, according 
to available data, folic acid supplementa-
tion does not appear to interfere with the 
therapeutic efficacy of MTX (17, 18). On 
the other hand, to date, there is no evidence 
that folinic acid, either at low or high dos-
age (less than/more than 5 mg/week), of-
fers additional benefit compared to folic 
acid for reducing/preventing MTX-related 
adverse events/intolerance. Furthermore, 
some evidence suggests that it may inter-
fere with the efficacy of MTX (increasing 
the number of tender joints). Moreover, 
higher costs would not justify folic acid re-
placement (18).
The recommendation was approved by 
89.5% of participants. 
Recommendation 4: monitoring for liver 
toxicity 
Transaminases (AST, ALT) are the most 
useful laboratory parameters for monitor-
ing liver toxicity due to MTX. Blood cells 
count and renal function tests should also 
be performed in patients receiving MTX. 
These tests should be performed every 2 
weeks for the first month, then every 4-12 
weeks to check for hepatic, haematological 
or renal toxicity (1; A). Neither chest X-rays 
nor respiratory function tests allow predic-
tion of the risk of MTX pneumonia (4; C).
This recommendation is unchanged in the 
new version, as no new significant evi-
dence was found in the literature. Recent 
studies confirm previous findings (19, 20).
The recommendation was approved by 
90.2% of participants. 
Recommendation 5: actions in the event 
of increased liver enzymes
When liver enzymes increase (≥2x normal 
upper limit), the dosage of MTX must be re-
duced or administration discontinued tem-
porarily. Persistently high values indicate 
that treatment should be discontinued. A 
liver biopsy is indicated when liver enzyme 
values are persistently high despite treat-
ment discontinuation and when other risk 
factors for liver disease are present (2b; C).
Nothing emerged from the literature review 
that warranted substantial changes to the 
2010 recommendation. There were no new 
randomized controlled trials (RCTs) com-
paring possible strategies for dealing with 
elevated liver enzyme levels during MTX 
treatment. The importance of reducing the 
dose, or temporary discontinuing therapy 
was confirmed (21, 22-25).
The recommendation was approved by 
89.2% of participants. 
Recommendation 6: long-term use of 
methotrexate
According to its safety profile, MTX may be 
used for long-term therapy. Discontinuation 
rates due to toxicity are similar to those in 
patients treated with hydroxychloroquine 
or leflunomide, and lower than those in pa-
tients receiving gold salts or sulfasalazine 
(3b). The most frequent side effects during 
treatment with MTX are gastrointestinal 
disturbances, with constant incidence over 
time, and hypertransaminasemia, especial-
ly during the first 5 years. The discontinua-
tion rate due to hepatotoxicity is about 5%. 
Alcohol consumption should be avoided, 
because it appears to be an adjunctive risk 
factor for the development of hepatic fibro-
sis. MTX is not a significant risk factor for 
the development of infections, including se-
vere infections. In patients with RA, MTX, 
and DMARDs in general, are associated 
with a greater incidence of tuberculosis 
reactivation (3b). MTX does not appear to 
be a risk factor for the development of neo-
plasms (3b). MTX can prolong the survival 
of RA patients by reducing cardiovascular 
mortality (2a).
In view of the safety profile of the drug, the 
2010 recommendation that MTX is appro-
priate for long-term use has been unequiv-
ocally confirmed. In addition, leflunomide 
has been added to the list of other disease-
modifying antirheumatic drugs (DMARDs) 
that have been compared with MTX; its 
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is comparable with that of MTX (26, 27). 
Concerning the risk of infections during 
MTX treatment, there is no specific risk 
for the development of a number of types 
of infections (including herpes zoster in-
fections and post-operative infections); 
however, as with other DMARDs, there 
was an increased incidence of tuberculosis 
(28,29). The absence of an increased risk 
of neoplasms was confirmed. Finally, the 
drug provides a potential protective effect 
against cardiovascular mortality in patients 
with RA treated with MTX who have con-
comitant heart disease (30-33). 
The recommendation was approved by 
90.2% of participants. 
Recommendation 7: treatment with meth-
otrexate in the event of orthopaedic sur-
gery
The administration of MTX (at ≤10 mg/
week) can be continued in RA patients who 
undergo orthopaedic surgery as MTX does 
not affect the incidence of perioperative 
surgical complications, whereas treatment 
discontinuation may increase the incidence 
of disease reactivation. MTX dosage reduc-
tion or treatment discontinuation may be 
considered for doses >10 mg per week in 
patients undergoing major surgery (1b; B).
This recommendation, corresponding to 
number 8 in the 2010 version, remains un-
changed in the present version, as no new 
evidence was found in the literature. The 
most recent publications have confirmed 
the result of previous studies. However, 
their findings are confined to low dose oral 
MTX given to patients undergoing ortho-
paedic surgery (34). There is no data on 
the use of higher doses, administered by 
parenteral route and to patients undergoing 
non-orthopaedic surgery. Thus, treatment 
decisions in individual cases must be made 
by the clinician (and surgeon) based on the 
patient’s condition and comorbidities, in 
particular on the global surgical and infec-
tion risk profile, the type of intervention 
proposed and on current therapy (whether 
combined with corticosteroids and/or other 
DMARDs). 
The recommendation was approved by 
85.4% of participants. 
Recommendation 8: treatment with meth-
otrexate and conception 
MTX must be discontinued at least 3 
months before conception (both in men 
and in women), it must be strictly forbid-
den during pregnancy and avoided during 
breastfeeding (4; C).
This recommendation, corresponding to 
number 9 in the 2010 version, has not been 
changed in the new version due to the lack 
of new evidence in the literature. The most 
recent publications have confirmed what 
had been reported previously (35-37).
The recommendation was approved by 
76.5% of participants. 
Recommendation 9: methotrexate as the 
first choice in rheumatoid arthritis pa-
tients 
MTX must be considered the DMARD of 
first choice in RA patients both alone and 
in combination (with low dosage glucocor-
ticoid and/or other DMARDs) (2b).
The evidence currently available, obtained 
from one meta-analysis and one double-
blind controlled RCT conducted on a cohort 
of patients with early RA, shows that, in the 
context of an MTX-based therapeutic strat-
egy (titrating MTX to the maximum toler-
ated dose and in any case to not more than 
25 mg/week until remission is achieved), 
the addition of a low-dose steroid improves 
outcomes, in terms of reduced radiographic 
progression and/or lower disease activity 
and less disability (38-42). 
The recommendation was approved by 
94.4% of participants. 
Recommendation 10: combined therapy 
in methotrexate non-responder patients 
In patients that are non-responders to MTX 
at the maximum tolerated dosage, combina-
tion therapy can be started with DMARD or 
a biological agent (1b). Currently, addition 
of a biological agent should be preferred 
in patients with poor prognostic factors or 
documented radiological progression (1b).
This recommendation has been amended in 
comparison with recommendation number 
12 in the 2010 version. A Cochrane review 
revealed that, considering the risk/benefit 
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advantage to combining MTX with other 
DMARDs compared to MTX alone when 
treating MTX naïve or MTX non-respond-
er patients (43). The only combination 
with a better risk/benefit profile than MTX 
alone was MTX + Hydroxychloroquine 
+ Sulfasalazine (44). Two recent studies 
have compared the efficacy and safety of 
this triple combination therapy to that of 
anti-TNF, revealing that the addition of a 
biological drug (not only anti-TNF) im-
proves both clinical and radiological out-
comes (45-48).
The recommendation was approved by 
76.5% of participants. 
Recommendation 11: discontinuation of 
methotrexate in the event of severe infec-
tions
Administration of MTX must be temporar-
ily discontinued in patients who develop 
severe infections (any infection requiring 
hospitalization and/or intravenous anti-
biotics/antifungals and/or presenting with 
sepsis or is life threatening, according to 
the NIH) (5; D).
This recommendation has not been modi-
fied in comparison with number 13 in the 
2010 version, because no new data emerged 
from the literature. Considering the im-
munosuppressive properties of MTX, the 
recommendation to suspend administration 
of the drug temporarily was considered ap-
propriate (49).
The recommendation was approved by 
94.7% of participants. 
Recommendation 12: discontinuation of 
methotrexate in the event of neutropenia
Administration of MTX must be discontin-
ued temporarily in patients who develop 
neutropenia (neutrophil count <1000). 
MTX can be reintroduced with caution 
in patients who have not developed other 
adverse reactions in association with neu-
tropenia (e.g., infections) and where neu-
tropenia has resolved spontaneously, after 
having considered the concomitant asso-
ciation with other risk factors for haema-
tological toxicity (5; D).
No evidence has emerged to justify updat-
ing this recommendation. In some obser-
vational studies, predictors of the onset of 
haematological toxicity were: renal failure, 
hypoalbuminemia, low blood levels of folic 
acid, absence of folic supplementation, old 
age, concomitant infection and pharmaco-
logical polytherapy. Therefore, when these 
risk factors are present, the clinician should 
be alert for signs of potential myelotoxici-
ty. However, it was pointed out that haema-
tological toxicity of MTX is rare and may 
appear both early (idiosyncratic reaction) 
and late (time- and dose-dependent) (50). 
The recommendation was approved by 
97.1% of participants. 
Recommendation 13: interventions in the 
event of nodulosis
MTX can be administered to patients with 
pre-existing rheumatoid nodules. The dos-
age of MTX should be reduced or adminis-
tration should be discontinued in patients 
who develop accelerated nodulosis during 
treatment (5; D).
This recommendation has not been changed 
in comparison with number 15 in the 2010 
version, due to the lack of new evidence. 
Worthy of note is that the 2010 Italian 
Consensus indicated that accelerated nodu-
losis should be addressed to the individual 
patient considering balance between resid-
ual disease activity and beneficial response 
to MTX therapy versus the possibility and 
the magnitude of side effects related to the 
drug (1).
The recommendation was approved by 
97.1% of participants. 
Recommendation 14: methotrexate in 
non-rheumatoid arthritis diseases 
MTX can be used:
- as a glucocorticoid-sparing drug in the 
long-term treatment of patients with gi-
ant cell arteritis (GCA) (1a), recent-onset 
rheumatic polymyalgia (PMR) (1b), mild-
to-moderate SLE with mainly skin and joint 
involvement (1b);
- to induce clinical remission in patients 
with recent-onset ANCA-associated vascu-
litis (AAV) with early systemic involvement 
(1b). It can also replace Azathioprine for 
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- in peripheral psoriatic arthritis (PsA), 
effective mainly on the cutaneous involve-
ment, but also efficacious on the joint com-
ponent (1b; B).
A few data also supports the possible use 
of MTX as an agent that can improve cu-
taneous involvement in recent-onset and 
widespread systemic sclerosis without sig-
nificant organ involvement (1b).
No evidence was found that warranted an 
update of the recommendation (51-54), 
in particular regarding the use of MTX in 
patients with recent-onset PMR and GCA 
(average disease duration <6 months) and 
with systemic lupus erythematosus (SLE). 
The current version, however, has extended 
the use of MTX to other non-RA diseases 
for which sufficiently valid supporting sci-
entific evidence (RCT) exists, including 
ANCA-associated vasculitis (AAV), in 
particular granulomatosis with polyangi-
itis (Wegener’s) and micropolyangiitis (51, 
55), psoriatic arthritis (PsA) (56-61) and 
systemic sclerosis (SSc) without signifi-
cant organ involvement, especially without 
renal or pulmonary involvement (62).
The recommendation was approved by 
91.2% of participants. 
Recommendation 15: possible discontinu-
ation of treatment with methotrexate due 
to achievement of clinical remission 
Therapeutic approach to RA patients who 
have achieved clinical remission with MTX 
alone or in combination with other agents.
In RA patients treated early (within 1 year 
of symptoms onset) who achieve and main-
tain clinical remission for ≥12 months, 
independently of the “tight control” thera-
peutic strategy and the DMARD discon-
tinuation methods adopted, treatment (in-
cluding MTX) can be discontinued in the 
attempt to achieve a “drug free remission”, 
which is feasible in 17-29% of patients.
In this recommendation, which was in-
troduced de novo in comparison with the 
original recommendations, attention has 
been focused for the first time on the thera-
peutic strategy to use for patients with RA 
who achieve MTX-induced clinical remis-
sion. In addition to the scarcity of studies 
on this subject, comparisons were hindered 
by the heterogeneous nature of the studies 
in terms of target populations, the defini-
tion and criteria identifying clinical remis-
sion and the therapeutic strategies adopted. 
Nevertheless, the analysis of the literature 
revealed that clinical remission is obtained 
more frequently in patients treated initially 
with combined therapy (with biological 
agents or DMARDs) or tightly controlled 
intensive therapy in comparison with 
those who receive standard treatment, i.e., 
DMARD alone or non-intensive conven-
tional management. It should be pointed 
out that discontinuing DMARDs, in the 
attempt to achieve drug-free remission, 
can be safely implemented only in a small 
percentage of patients (63-69). There is 
no evidence supporting any one DMARD 
discontinuation method over another; the 
drug-free remission rate is 12% after five 
years of follow-up (70).
The recommendation was approved by 
85.7% of participants. 
n	 DISCUSSION
This update of the 2010 Italian recommen-
dations on the use of MTX in rheumatic 
diseases, is the result of a detailed review 
of the literature published between 2008 
and 2012 on the treatment of patients with 
RA or non-RA rheumatologic diseases 
with MTX. The recommendations are 
based on a high level of evidence, showing 
the robustness of the qualitative and quan-
titative supporting data used, which was 
generally obtained from important studies 
(meta-analyses and RCTs). As in 2010, the 
complexity of the topic MTX in rheumatol-
ogy is reflected in the variety of the issues 
investigated, with addition of the new topic 
on the therapeutic approach to patients with 
RA in remission. The literature analysis re-
vealed that clinical research is focused on 
determining the best therapeutic strategy, 
the safety profile and the potential efficacy 
of combination therapies. Thus, it may be 
assumed that early and intensive treatment 
could be more effective in order to preserve 
joint function and quality of life.
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the American College of Rheumatology 
(71), the present recommendations have 
been drawn up considering the typical pa-
tient and are therefore fully applicable to 
clinical practice only after the clinician 
evaluates the individual risk/benefit ratio 
and adapts the treatment proposed for each 
patient.
In summary, this update offers indications 
for good clinical practice, in order to sup-
port the Rheumatologist in addressing a 
number of common clinical issues, in light 
of evidence-based medicine.
Obviously, the publication of new scien-
tific findings, as well as the emergence of 
new significant clinical issues, will deter-
mine the need for further modifications and 
updates of these recommendations.
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